LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Executive Changes at NuVasive
Company News

Executive Changes at NuVasive

March 26, 2014 2 min read Premium comments

Advertisement

Executive Changes at NuVasive
Michael Paolucci and QuentinBlackford/NuVasive
Secondary

NuVasive, Inc., a company focusing on minimally disruptive products and procedures, is announcing major executive leadership changes.

Quentin Blackford has been promoted to the Executive Leadership Committee as Executive Vice President of Finance and Investor Relations. Blackford joined NuVasive in 2009, and with nearly 15 years of financial experience within medical device organizations, his effort and insight will be invaluable as NuVasive drives toward $1 billion and beyond in revenues with improved profitability.

The company also announced the resignation of Craig Hunsaker, Senior Vice President of Global Human Resources, which will be effective March 31, 2014. Hunsaker will assist in the transition of his responsibilities to Mike Paolucci, who has been appointed Executive Vice President of Global Human Resources, effective immediately.

Mike Paolucci joins NuVasive from Life Technologies Corporation, a global life sciences company with over $4 billion in revenue, which was recently acquired by Thermo Fisher Scientific. He brings more than 20 years of broad global human resources experience at the executive and board level that will be instrumental to NuVasive’s evolution into a larger, global business. At Life Technologies, Paolucci was responsible for the global compensation and benefit programs that encompassed more than 10, 000 employees in nearly 40 countries. He also served as a human resources business partner for various business segments and was responsible for the company’s human resources technology systems. Prior to Life Technologies, he served as vice president in various human resources capacities at Hewlett-Packard and EDS Corporation, from 2000 to 2009.

Chairman and CEO Alex Lukianov said, “We are exceptionally grateful to Craig for all of his contributions during his tenure with NuVasive. I am thrilled to welcome both Quentin and Mike to the NuVasive Executive Committee. Their strong propensity for outstanding standards, steadfast focus, and wealth of experience in achieving excellent outcomes will be instrumental to our executive leadership team. I look forward to their contributions and have tremendous confidence in the team we have organized to help us achieve our market share taking strategy.”

Mike Paolucci told OTW, “NuVasive has a rich history and culture that has enabled the organization to be the spine industry leader. I see my role as enhancing the current culture through improving the effectiveness of Human Resource programs, policies and processes that will also allow the business and our customers to achieve their goals. This will also allow us to attract the best talent in our industry and continually grow and development our Shareowners—the most important asset we have.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy